Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > SCOTTY

<< Previous

Bullboard Posts

Next >>

Comment by Dude51on Apr 18, 2021 5:10pm

194 Views

Post# 33019538

RE:SCOTTY

Scotty we are not the one who called this stock a shell company made disparaging comments about management. You also insinuate where's the money coming from like something nefarious is going on. How does it feel to be bashed? I think you owe us the investors an apology for being a dickwad with your comments. You certainly were not helping and may have caused weak hand to fold, that’s the problem with your comments. It’s our money your screwing with, do you not understand?

<< Previous

Bullboard Posts

Next >>

Meet Canopy USA’s new CEO, Brooks Jorgensen